VectorBuilder' s partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy, UC101, received Investigational New Drug (IND) approval from the U.S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback